Last reviewed · How we verify
TAFLUPROST 0.0015% EYEDROPS
TAFLUPROST 0.0015% EYEDROPS is a Small molecule drug developed by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia. It is currently FDA-approved. Also known as: Saflutan, MSD.
At a glance
| Generic name | TAFLUPROST 0.0015% EYEDROPS |
|---|---|
| Also known as | Saflutan, MSD |
| Sponsor | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution) (NA)
- Tafluprost Preservative Free Switch Study (PHASE4)
- Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
- Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) (PHASE3)
- The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (PHASE4)
- A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT (PHASE1, PHASE2)
- A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAFLUPROST 0.0015% EYEDROPS CI brief — competitive landscape report
- TAFLUPROST 0.0015% EYEDROPS updates RSS · CI watch RSS
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia portfolio CI
Frequently asked questions about TAFLUPROST 0.0015% EYEDROPS
What is TAFLUPROST 0.0015% EYEDROPS?
TAFLUPROST 0.0015% EYEDROPS is a Small molecule drug developed by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia.
Who makes TAFLUPROST 0.0015% EYEDROPS?
TAFLUPROST 0.0015% EYEDROPS is developed and marketed by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (see full Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia pipeline at /company/azienda-socio-sanitaria-territoriale-degli-spedali-civili-di-brescia).
Is TAFLUPROST 0.0015% EYEDROPS also known as anything else?
TAFLUPROST 0.0015% EYEDROPS is also known as Saflutan, MSD.
What development phase is TAFLUPROST 0.0015% EYEDROPS in?
TAFLUPROST 0.0015% EYEDROPS is FDA-approved (marketed).
Related
- Manufacturer: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia — full pipeline
- Also known as: Saflutan, MSD
- Compare: TAFLUPROST 0.0015% EYEDROPS vs similar drugs
- Pricing: TAFLUPROST 0.0015% EYEDROPS cost, discount & access